The latest update is out from Ultragenyx Pharmaceutical (RARE).
At Ultragenyx Pharmaceutical Inc.’s Annual Meeting on June 18, 2024, stockholders voted on several key proposals, including the election of Class II Directors and amendments to the company’s incentive plan. The Amended and Restated 2023 Incentive Plan was approved, along with the election of all Class II Director nominees. Additionally, stockholders ratified Ernst & Young LLP as the company’s independent accounting firm and endorsed executive compensation. With a strong turnout, these decisions mark a roadmap for Ultragenyx’s strategy and governance in the coming years.
For a thorough assessment of RARE stock, go to TipRanks’ Stock Analysis page.
